Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.
Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Günthard HF, Rusert P, Trkola A. Ruprecht CR, et al. Among authors: abela ia. J Exp Med. 2011 Mar 14;208(3):439-54. doi: 10.1084/jem.20101907. Epub 2011 Feb 28. J Exp Med. 2011. PMID: 21357743 Free PMC article.
Correlates of broadly neutralizing antibody development.
Abela IA, Kadelka C, Trkola A. Abela IA, et al. Curr Opin HIV AIDS. 2019 Jul;14(4):279-285. doi: 10.1097/COH.0000000000000552. Curr Opin HIV AIDS. 2019. PMID: 31107283 Free article. Review.
Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study.
Ulyte A, Radtke T, Abela IA, Haile SR, Braun J, Jung R, Berger C, Trkola A, Fehr J, Puhan MA, Kriemler S. Ulyte A, et al. Among authors: abela ia. Int J Public Health. 2020 Dec;65(9):1549-1557. doi: 10.1007/s00038-020-01495-z. Epub 2020 Oct 15. Int J Public Health. 2020. PMID: 33063141 Free PMC article.
Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.
Ulyte A, Radtke T, Abela IA, Haile SR, Blankenberger J, Jung R, Capelli C, Berger C, Frei A, Huber M, Schanz M, Schwarzmueller M, Trkola A, Fehr J, Puhan MA, Kriemler S. Ulyte A, et al. Among authors: abela ia. BMJ Open. 2021 Jul 26;11(7):e047483. doi: 10.1136/bmjopen-2020-047483. BMJ Open. 2021. PMID: 34312201 Free PMC article.
A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B, Chammartin F, Smith D, Stoeckle MP, Amico P, Eichenberger AL, Hasse B, Schuurmans MM, Müller T, Tamm M, Dickenmann M, Abela IA, Trkola A, Hirsch HH, Manuel O, Cavassini M, Hemkens LG, Briel M, Mueller NJ, Rauch A, Günthard HF, Koller MT, Bucher HC, Kusejko K; study groups from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. Speich B, et al. Among authors: abela ia. Trials. 2021 Oct 21;22(1):724. doi: 10.1186/s13063-021-05664-0. Trials. 2021. PMID: 34674742 Free PMC article.
64 results